CoChat

Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies

Open access
Heslop, James A., Hammond, Thomas G., Santeramo, Ilaria, Tort Piella, Agnès, Hopp, Isabel, Zhou, Jing, Baty, Roua, Graziano, Enrique I., Proto Marco, Bernabé, Caron, Alexis, Sköld, Patrik, Andrews, Peter W., Baxter, Melissa A., Hay, David C., Hamdam, Junnat, Sharpe, Michaela E., Patel, Sara, Jones, David R., Reinhardt, Jens, Danen, Erik H.J., Ben-David, Uri, Stacey, Glyn, Björquist, Petter, Piner, Jacqueline, Mills, John, Rowe, Cliff, Pellegrini, Giovanni, Sethu, Swaminathan, Antoine, Daniel J., Cross, Michael J., Murray, Patricia, Williams, Dominic P., Kitteringham, Neil R., Goldring, Chris E.P., Park, B. Kevin · 2015 · Stem Cells Translational Medicine
Cited by 139

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. However, despite the undoubted potential held by these therapies, the balance between risk and benefit remains difficult to predict. As in any new field, a lack of previous application in man and gaps in the underlying science mean that regulators and investigators continue to look for a balance between minimizing potential risk and ensuring therapies are not needlessly kept from patients. Here, we attempt to identify the important safety issues, assessing the current advances in scientific knowledge and how they may translate to clinical therapeutic strategies in the identification and management of these risks. We also investigate the tools and techniques currently available to researchers during preclinical and clinical development of stem cell products, their utility and limitations, and how these tools may be strategically used in the development of these therapies. We conclude that ensuring safety through cutting-edge science and robust assays, coupled with regular and open discussions between regulators and academic/industrial investigators, is likely to prove the most fruitful route to ensuring the safest possible development of new products.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5966/sctm.2014-0110

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 139

Metadata

Authors
Heslop, J. A., Hammond, T. G., Santeramo, I., Tort Piella, A., Hopp, I., Zhou, J., Baty, R., Graziano, E. I., Proto Marco, B., Caron, A., Sköld, P., Andrews, P. W., Baxter, M. A., Hay, D. C., Hamdam, J., Sharpe, M. E., Patel, S., Jones, D. R., Reinhardt, J., Danen, E. H. J., Ben-David, U., Stacey, G., Björquist, P., Piner, J., Mills, J., Rowe, C., Pellegrini, G., Sethu, S., Antoine, D. J., Cross, M. J., Murray, P., Williams, D. P., Kitteringham, N. R., Goldring, C. E. P., & Park, B. K.
Venue
Stem Cells Translational Medicine
Published
2015-02-26
Volume
4
Issue
4
Pages
389-400
ISSN
  • 2157-6564 (ISSN-L)
  • 2157-6580
OpenAlex
W1998782859
Cited by
139
References
21
FWCI
11.19
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies. https://app.cochat.ai/papers/10.5966/sctm.2014-0110
The paper
Heslop, J. A., Hammond, T. G., Santeramo, I., Tort Piella, A., Hopp, I., Zhou, J., Baty, R., Graziano, E. I., Proto Marco, B., Caron, A., Sköld, P., Andrews, P. W., Baxter, M. A., Hay, D. C., Hamdam, J., Sharpe, M. E., Patel, S., Jones, D. R., Reinhardt, J., . . . Park, B. K. (2015). Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies. Stem Cells Translational Medicine. https://doi.org/10.5966/sctm.2014-0110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.